v3.22.2.2
Revenue
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Our disaggregated revenues were as follows (in thousands):
Three Months Ended
 September 30,		Nine Months Ended
September 30,
2022202120222021
Royalties$99,551 $58,563 $254,496 $141,264 
Product sales, net:
  Sales of bulk rHuPH20$19,259 $18,862 $60,764 $59,719 
Sales of proprietary products24,180 6,185 44,559 17,454 
Sales of device partnered products17,988 — 24,544 — 
Total product sales, net$61,427 $25,047 $129,867 $77,173 
Revenues under collaborative agreements:
  Upfront license and target nomination fees$— $2,000 $30,000 $42,000 
  Event-based development and regulatory milestones and other fees44,000 — 59,000 30,000 
  Sales-based milestones— 30,000 — 50,000 
  Device Licensing and development revenue3,998 220 5,257 870 
Total revenues under collaborative agreements$47,998 $32,220 $94,257 $122,870 
Total revenue$208,976 $115,830 $478,620 $341,307 
During the three months ended September 30, 2022 we recognized revenue related to licenses granted to partners in prior periods in the amount of $143.6 million. This amount represents royalties earned in the current period in addition to $44.0 million of variable consideration in the contracts where uncertainties have been resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $0.5 million during the three months ended September 30, 2022 that had been included in deferred revenues in the condensed consolidated balance sheets as of December 31, 2021.
During the nine months ended September 30, 2022 we recognized revenue related to licenses granted to partners in prior periods in the amount of $313.5 million. This amount represents royalties earned in the current period in addition to $59.0 million of variable consideration in the contracts where uncertainties have been resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $1.5 million during the nine months ended September 30, 2022 that had been included in deferred revenues in the condensed consolidated balance sheets as of December 31, 2021. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods
Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands):
September 30, 2022December 31, 2021
Accounts receivable, net$164,135 $90,975 
Contract assets69,167 — 
Deferred revenues6,419 4,276 
As of September 30, 2022, the amounts included in the transaction price of our contracts with customers and allocated to goods and services not yet provided were $97.2 million, of which $90.8 million relates to unfulfilled purchase commitments and $6.4 million has been collected and is reported as deferred revenues in the condensed consolidated balance sheets. The unfulfilled purchase commitments are estimated to be delivered by the end of 2023. Of the total deferred revenues of $6.4 million, $3.6 million is expected to be used by our customers within the next 12 months.
We recognized contract assets of $69.2 million as of September 30, 2022, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods